Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksC4x Discry Hdgs Regulatory News (C4XD)

Share Price Information for C4x Discry Hdgs (C4XD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.30
Bid: 9.30
Ask: 9.98
Change: -0.36 (-3.60%)
Spread: 0.68 (7.312%)
Open: 9.30
High: 9.30
Low: 9.30
Prev. Close: 10.00
C4XD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

C4XD forms Drug Discovery Advisory Network

2 Sep 2019 07:00

RNS Number : 8012K
C4X Discovery Holdings PLC
02 September 2019
 

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

 

C4X Discovery forms Drug Discovery Advisory Network

 

World-renowned drug discovery experts to advance C4XD capabilities

 

2 September 2019 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that Robin Carr, a renowned industry veteran who has worked at GSK and Astex, is to head up and form a C4XD Drug Discovery Advisory Network. 

 

The Advisory Network will bring together small molecule drug discovery and development experts from across the globe. It has been formed to harness industry expertise to build on C4XD's drug discovery capabilities and attract valuable relationships that have the potential to advance its goal of becoming the world's most productive drug discovery company. Robin and his team will act as ambassadors for C4XD within the Biotech and Pharmaceutical community, building awareness of C4XD's technologies, capabilities and business. Through their extensive relationships and industry knowledge, they will identify pioneering complementary drug discovery technologies and collaborators that have the potential to accelerate or improve delivery of C4XD's portfolio.

 

Clive Dix, Chief Executive Officer of C4XD, said: "We are delighted to announce the formation of our Advisory Network and to be working closely with prestigious world leading experts in drug discovery. As part of our strategy to become the world's most productive drug discovery company, we are continually enhancing both our network and expertise. As international thought leaders, the Advisory Network's deep industry expertise will enable us to accelerate progress of our portfolio and we are particularly proud that Robin will be Chair. Under Robin's guidance, we believe the Advisory Network will advance our vision and reputation within the industry."

 

Robin Carr, added: "C4XD is an inspiring young company at the forefront of drug discovery with cutting edge technologies and scientists of the highest calibre. Their openness to collaboration and working with complementary technologies creates a new frontier in bringing novel approaches to the creation of future medicines. I am honoured and excited to be working with the C4XD team and to building the Advisory Network that will add value in an innovative and collaborative way."

 

Chair of the C4XD Drug Discovery Advisory Network - Robin Carr

Robin has thirty years of experience in drug discovery and has held senior roles in Glaxo Wellcome, GSK and Astex Therapeutics. At GSK, he was senior Vice President of Drug Design and Selection and held global responsibility for GSK's small molecule and biopharm drug discovery platforms. At Astex Therapeutics, Robin was VP Drug Discovery, with responsibility for its internal and partnered discovery programmes.

 

Robin's scientific focus is innovative approaches to small molecule drug discovery, specifically fragment-based discovery, DNA encoded libraries, covalent drug discovery, protein degradation and the integration of chemical technologies in into structure and predictive modelling-based drug design.

 

During his career, Robin has worked on seven small molecule programmes that have progressed into the clinic, of which, two have achieved approval within oncology. Robin has published over 40 peer reviewed papers and patents.

 

Robin has a PhD in Chemistry from Northwestern University and a BSc in Organic Chemistry from Imperial College, London.

 

Further Advisory Network members will be announced in due course.

 

- Ends -

 

Contacts

 

C4X Discovery Holdings

Mo Noonan, Communications

+44 (0)787 6444977

Panmure Gordon (UK) Limited (NOMAD and Broker)

 

Freddy Crossley, Emma Earl (Corporate Finance)

+44 (0)20 7886 2500

James Stearns (Corporate Broking)

C4X Discovery Media - Consilium Strategic Communications

Mary-Jane Elliott, Chris Gardner, Matthew Neal

+44 (0)203 709 5700

 

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery (C4XD) aims to create the world's most productive drug discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m.

 

C4XD has a state-of-the-art suite of proprietary technologies across the drug discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division. The Company is led by a highly experienced management team and Board who have delivered significant

value creation within the healthcare sector.

 

For additional information please go to: www.c4xdiscovery.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCBFLLBKKFBBBZ
Date   Source Headline
27th Mar 20247:00 amRNSProposed Voluntary Delisting
27th Mar 20247:00 amRNSInterim results
23rd Jan 20241:57 pmRNSResult of AGM
18th Jan 20247:00 amRNSBoard Update
4th Jan 20242:45 pmRNSHolding(s) in Company
3rd Jan 20247:00 amRNSAstraZeneca $11m milestone payment to C4XD
18th Dec 20233:31 pmRNSPosting of 2023 Annual Report and Notice of AGM
14th Dec 20237:00 amRNSFull Year Results
7th Dec 20237:00 amRNSNotice of Results
5th Oct 20232:35 pmRNSHolding(s) in Company
2nd Oct 202312:36 pmRNSBlock listing Interim Review
29th Sep 202311:14 amRNSGrant of Options and Directors Dealing
28th Sep 20233:52 pmRNSHolding(s) in Company
1st Sep 20237:00 amRNSTotal Voting Rights
18th Aug 202312:45 pmRNSExercise of Options, Issue of Equity and TVR
1st Aug 20237:00 amRNSDivestment of Orexin-1 to Indivior for £15.95m
20th Jun 20237:00 amRNSC4X Discovery Holdings plc: Board Change
1st Jun 20237:00 amRNSMALT-1 Inhibitor Programme Update
26th Apr 20237:00 amRNSHalf Year Results
19th Apr 20237:00 amRNSNotice of Results
8th Mar 20232:49 pmRNSBlock Listing Interim Review
22nd Feb 20237:00 amRNSC4XD and Garvan Institute collaboration
24th Jan 202311:47 amRNSResult of AGM
19th Jan 20237:00 amRNSMALT-1 Inhibitor Programme Update
10th Jan 20237:00 amRNSNick Ray Appointed as Chief Scientific Officer
19th Dec 20224:52 pmRNSPosting of 2022 Annual Report and Notice of AGM
15th Dec 20227:00 amRNSFull Year Results
28th Nov 20222:31 pmEQSC4X Discovery signs potential $402mln deal
28th Nov 20229:00 amRNSNotice of Final Results
28th Nov 20227:00 amRNSC4XD Agreement with AstraZeneca
1st Nov 20222:03 pmRNSExercise of Options, Issue of Equity and TVR
20th Oct 20227:00 amRNSC4XD and HitGen to collaborate in inflammation
4th Oct 20222:56 pmRNSHolding(s) in Company
22nd Sep 20224:40 pmRNSSecond Price Monitoring Extn
22nd Sep 20224:35 pmRNSPrice Monitoring Extension
31st Aug 202211:10 amRNSHolding(s) in Company
17th Aug 20224:06 pmRNSHolding(s) in Company
17th Aug 20223:43 pmRNSHolding(s) in Company
16th Aug 20222:17 pmRNSHolding(s) in Company
11th Aug 202212:43 pmRNSResult of Placing to Raise £5.7 million
11th Aug 20227:00 amRNSProposed Placing to Raise Up To £5.7 million
2nd Aug 20227:00 amRNSBusiness Update
1st Aug 20223:09 pmRNSBlock Listing Interim Review
6th Jul 20227:00 amRNSC4X Discovery receives Sanofi milestone payment
28th Jun 20225:46 pmRNSAIM Rule 17 Schedule 2(g) Update
28th Apr 20227:00 amRNSHalf Year Results
19th Apr 20227:00 amRNSNotice of Results
28th Feb 20225:30 pmRNSExercise of Options, Issue of Equity and TVR
3rd Feb 20227:00 amRNSGrant of Options and Directors Dealing
1st Feb 20227:00 amRNSBlock listing Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.